Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 11/20 | 0.60 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.60 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13889166 | 0.75 | KDM1A (0.68) | KDM1AKDM1BDGAT1KCNH2HTR2A | |
| SCHEMBL2358633 | 0.73 | KDM1A (0.60) | KDM1AKDM1BDGAT1KCNH2HTR2A | |
| SCHEMBL25982894 | 0.72 | KDM1A (0.58) | KDM1AHTR2AHTR2CHTR2BALDH1A1 | |
| SCHEMBL446822 | 0.72 | KDM1A (0.58) | KDM1AKDM1BHTR2AHTR2CHTR2B | |
| SCHEMBL446823 | 0.72 | KDM1A (0.58) | KDM1AKDM1BHTR2AHTR2CHTR2B | |
| SCHEMBL4716381 | 0.72 | KDM1A (0.58) | KDM1AKDM1BDGAT1ALDH1A1 | |
| SCHEMBL5264685 | 0.72 | KDM1A (0.58) | KDM1AKDM1BDGAT1ALDH1A1 | |
| SCHEMBL2827719 | 0.71 | KDM1A (0.52) | KDM1AKDM1BKCNH2HTR2CHTR2B | |
| SCHEMBL2854689 | 0.71 | KDM1A (0.52) | KDM1AKDM1BKCNH2HTR2CHTR2B | |
| SCHEMBL2324658 | 0.71 | KDM1A (0.52) | KDM1AKDM1BKCNH2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | PDE4A, PDE12, PDE4B | KDM1A 613/4885KDM1B 1290/4885DGAT1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.